The veterinary pharmaceutical giant is navigating one of the most turbulent stretches in its recent history, with the stock touching fresh lows even as a prominent investment house has chosen this exact moment to build a nine-figure position. The divergence in investor behavior underscores just how contested the outlook for Zoetis has become.
Shares bottomed out at 61.98 euros on Monday, a new 52-week trough, before staging a modest rebound to 65.20 euros the following day—a 0.90 percent gain. That short-lived bounce did little to shift the prevailing mood, particularly after management confirmed that July brought no improvement in the market trends that have been weighing on the business. Price-sensitive pet owners and more aggressive discounting from rivals continue to squeeze the company’s core companion-animal franchise.
A Guidance Cut That Reshaped the Debate
The current malaise traces back to a sharp reduction in full-year targets announced after the second quarter. Zoetis now expects adjusted earnings per share of $6.15 to $6.25, a significant step down from the previous range of $6.85 to $7.00. Revenue guidance was similarly trimmed, with the company now projecting $9.12 billion to $9.32 billion for 2026, down from an earlier forecast of $9.68 billion to $9.96 billion.
The second quarter itself, which ended June 30, delivered revenue of $2.468 billion and adjusted diluted EPS of $1.87. While the companion-animal segment—historically the company’s growth engine—dragged on results, the livestock division proved comparatively resilient and offset a portion of the weakness, according to company statements.
The market’s reaction tells its own story. The stock now sits just 4.26 percent above its 52-week low, and it has lost 39.81 percent since the start of the year. A 2.83 percent advance on Monday to 64.62 euros offered a tentative sign of stabilization, though investors remain wary given the absence of any clear inflection point in U.S. demand.
Analysts Split on the Path Forward
Wall Street’s response to the guidance revision has been anything but uniform. JPMorgan Chase trimmed its price target from $130 to $115 on Friday while maintaining an Overweight rating, suggesting the bank still sees value despite the lowered outlook. UBS took a more cautious stance, cutting its target to $80 with a Neutral rating—a clear signal that a swift recovery is far from guaranteed.
William Blair went a step further, downgrading the stock from Outperform to Market Perform in a move that reflects growing skepticism about the near-term growth narrative. BNP Paribas, meanwhile, slashed its target dramatically from $146 to $110 but held onto its Outperform rating, indicating continued confidence in a medium-term rebound. Across the Street, price targets now cluster in a range between $80 and $115, with most firms settling on a neutral-to-moderately-positive posture.
Should investors sell immediately? Or is it worth buying Zoetis?
Institutional Positions Diverge Sharply
The ownership picture is equally fractured. BlackRock disclosed in a July 30 filing that it held 37,660,315 Class A shares, representing a 9.0 percent stake as of the end of June. Renaissance Technologies, by contrast, cut its position by 40.7 percent during the first quarter and now holds approximately 252,000 shares.
Perhaps the most striking counter-move came from Ruane Cunniff & Goldfarb, which opened a new position worth roughly $286.7 million in late July—enough to make it the firm’s tenth-largest holding. The contrast could hardly be starker: some investors are heading for the exits while others see the current valuation as an entry point worth backing with real money.
New Leadership, New Priorities
Amid the operational strain, Zoetis is pushing forward with a significant leadership transition. Jay Saccaro, recruited from GE HealthCare, assumes the newly created dual role of Chief Financial Officer and Chief Operating Officer on August 17. The outgoing finance chief, Wetteny Joseph, will remain as a special advisor to the CEO, supporting the transition into early 2027.
The timing is notable—the leadership shake-up coincides with the most severe guidance correction in recent memory, raising the stakes for Saccaro as he steps into a role that will require both financial discipline and operational firepower.
On the strategic front, the company closed its acquisition of VitalRADS on Thursday, adding a veterinary teleradiology platform to its portfolio. The deal is designed to bolster Zoetis’ diagnostics and AI-powered imaging capabilities—an area that could deliver growth beyond the margin-constrained mass market for pet products.
With a market capitalization of roughly 25.99 billion euros, Zoetis is a fraction of its former self; just a year ago, in August 2025, the stock hit a 52-week high of 137.00 euros. The question now is whether the livestock business can serve as a stable anchor while the company attempts a reset on two fronts: reviving pet-care demand and integrating new leadership at a moment when every decision will be scrutinized.
Ad
Zoetis Stock: Buy or Sell?! New Zoetis Analysis from August 11 delivers the answer:
The latest Zoetis figures speak for themselves: Urgent action needed for Zoetis investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 11.
Zoetis: Buy or sell? Read more here...
